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Abstract
Background: While there is significant interest in combining anti-angiogenesis therapy with conventional anti-cancer
treatment, clinical trials have as of yet yielded limited therapeutic gain, mainly because mechanisms of anti-angiogenic
therapy remain to a large extent unknown. Currently, anti-angiogenic tumor therapy is conceptualized to either ‘‘normalize’’
dysfunctional tumor vasculature, or to prevent recruitment of circulating endothelial precursors into the tumor. An
alternative biology, restricted to delivery of anti-angiogenics immediately prior to single dose radiotherapy (radiosurgery), is
provided in the present study.
Methodology/Principal Findings: Genetic data indicate an acute wave of ceramide-mediated endothelial apoptosis,
initiated by acid sphingomyelinase (ASMase), regulates tumor stem cell response to single dose radiotherapy, obligatory for
tumor cure. Here we show VEGF prevented radiation-induced ASMase activation in cultured endothelium, occurring within
minutes after radiation exposure, consequently repressing apoptosis, an event reversible with exogenous C16-ceramide.
Anti-VEGFR2 acts conversely, enhancing ceramide generation and apoptosis. In vivo, MCA/129 fibrosarcoma tumors were
implanted in asmase
+/+ mice or asmase
2/2 littermates and irradiated in the presence or absence of anti-VEGFR2 DC101 or
anti-VEGF G6-31 antibodies. These anti-angiogenic agents, only if delivered immediately prior to single dose radiotherapy,
de-repressed radiation-induced ASMase activation, synergistically increasing the endothelial apoptotic component of tumor
response and tumor cure. Anti-angiogenic radiosensitization was abrogated in tumors implanted in asmase
2/2 mice that
provide apoptosis-resistant vasculature, or in wild-type littermates pre-treated with anti-ceramide antibody, indicating that
ceramide is necessary for this effect.
Conclusions/Significance: These studies show that angiogenic factors fail to suppress apoptosis if ceramide remains
elevated while anti-angiogenic therapies fail without ceramide elevation, defining a ceramide rheostat that determines
outcome of single dose radiotherapy. Understanding the temporal sequencing of anti-angiogenic drugs and radiation
enables optimized radiosensitization and design of innovative radiosurgery clinical trials.
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Introduction
There is general interest in combining anti-angiogenesis therapy
with conventional anti-cancer treatment, and clinical trials are
underway testing a variety of agents[1]. The original concept was
that anti-angiogenic treatment would act to ‘‘choke off’’ a growing
tumor that has a burgeoning need for blood vessels to provide
oxygen and nutrients[2]. Recent adaptations of this concept
conceive anti-angiogenic therapy to act by two differing, though
non-mutually exclusive, mechanisms. One postulates anti-angio-
genesis prevents VEGF-dependent recruitment of endothelial
precursors into nascent or damaged tumor vasculature[3], while
the other proposes anti-angiogenic therapies ‘‘normalize’’ dys-
functional tumor vasculature thereby improving perfusion and
drug delivery[3,4]. Although the outcome of some clinical studies
are consistent with either of these hypotheses[3,4], to date anti-
angiogenesis therapy has yielded only modest gains. It thus
appears that while anti-angiogenesis may have potential impact in
anti-cancer therapy, its mode of application has so far not been
optimized, limiting its utility.
We recently reported that single dose radiotherapy induces a
rapid wave of endothelial cell apoptosis in radioresponsive tissues,
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with direct damage to tissue-specific stem cells to determine organ
fate[5,6,7,8]. We termed this event the vascular component of the
tumor (or tissue) response, and showed that its abrogation in acid
sphingomyelinase (ASMase)-, Bak-, or Bax-deficient mice resulted
in resistance to single dose radiotherapy. We also showed [8] that
Bax and Bak have non-redundant functional roles in the apoptotic
response of the irradiated intestinal endothelium. Pre-treatment
with angiogenic basic fibroblast growth factor (bFGF) mimicked
the asmase
2/2 phenotype[5]. Endothelial cells preferentially
manifest 20-fold enrichment of a non-lysosomal secretory form
of ASMase[9] that renders them particularly vulnerable to
radiation-induced ASMase-mediated generation of the pro-
apoptotic second messenger ceramide[10], and evidence indicates
ceramide-mediated apoptosis is causative of the vascular compo-
nent of tumor response to single dose radiotherapy[10]. While
these studies employed genetic inactivation of endothelial
apoptosis to argue that tissue damage occurred by a combined
effect of direct damage to stem cells coupled to vascular
dysfunction, here we test the hypothesis that anti-angiogenesis
therapy might act in converse, targeting the vascular component,
de-repressing this system in order to radiosensitize. The present
studies show that the ceramide level serves as a radiation rheostat
that regulates the balance between endothelial cell survival and
death, and ultimately tumor response. Utilization of anti-
angiogenic drugs based on the principle of enhancing ceramide
signaling resulted in conversion of tumor growth delay to tumor
cure after single dose radiotherapy.
Results
VEGF and bFGF inhibit radiation-induced apoptosis via
repression of ASMase activation
VEGF and bFGF inhibit radiation-induced endothelial apop-
tosis in vitro and in vivo[11,12], although the mechanism remains
only partially known. While bFGF was shown to inhibit
endothelial apoptosis via repression of ASMase-mediated cer-
amide elevation[13], a similar effect of VEGF has not been
reported. Here we show that the increase in ASMase activity in
bovine aortic endothelial cells (BAEC), which occurs almost
immediately after 10 Gy from a baseline of 16866 nmol/mg/min
to peak at 289615 nmol/mg/min at 1.5 min (Figure 1A;
p,0.005), was abrogated by pre-treatment with VEGF-165,
VEGF-121 (Figure 1A;p ,0.005 each vs. radiation alone) or
bFGF (Figure S1A;p ,0.005 vs. radiation alone). Concomitant
radiation-induced increases of neutral sphingomyelinase (NSMase)
or ceramide synthase activity were not detected (not shown).
Whereas ASMase translocation to the external leaflet of the
plasma membrane precedes ASMase-mediated sphingomyelin
hydrolysis to ceramide in diverse stress systems[14], we show that
in BAEC surface ASMase protein, detected by FACS (see
Supplementary Methods S1), increased by 2 min post 10 Gy
from a baseline in 1061% to a maximum of 2961% of the total
cell population (Figure S1B;p ,0.01 vs. non-irradiated control),
and was almost completely inhibited by 10 min pre-treatment with
1 ng/ml bFGF (p,0.01 vs. radiation alone). Similarly, pre-
treatment with 2 ng/ml VEGF-165 or VEGF-121 almost
completely inhibited radiation-induced ASMase translocation
(not shown), resulting in inhibition of radiation-induced ceramide
elevation (Figure 1B;p ,0.01 for each VEGF plus radiation vs.
10 Gy alone), thus mimicking bFGF (Figure S1C;p ,0.01).
Inhibition of radiation-induced ceramide elevation by VEGF and
bFGF was also observed in human coronary aortic endothelial
cells (HCAEC) (Figure S2).
As anticipated, based on prior studies[11], ceramide repression
by VEGF and bFGF was followed by inhibition of radiation-
induced endothelial apoptosis (assessed by bis-benzimide staining)
in VEGF-165- (Figure 1C), VEGF-121- (Figure S3A) or bFGF-
(Figure S4) pre-treated BAEC (p,0.01 each vs. 10 Gy alone at
all times from 4–8 h) or HCAEC (Figure S5;p ,0.01 each vs.
20 Gy alone at 9–12 h). Similar anti-apoptotic protection was
demonstrated using the caspase 3 activity assay, which increased
5.7-fold of control by 4 h after 10 Gy, reduced to 2.7-fold by
VEGF-165 (p,0.05, Figure 1D), 2.6-fold by VEGF-121 (Figure
S3B;p ,0.05), and nearly abrogated by bFGF (Figure S6,
p,0.001 vs. 10 Gy).
To confirm the critical role of ceramide in signaling apoptosis in
this cell system, a small amount of long-chain natural C16-
ceramide (1 mM) was added 30 min prior to irradiation, with or
without pre-treatment with VEGF or bFGF. This amount of C16-
ceramide alone did not confer apoptosis for as long as 8 h, and did
not significantly increase radiation-induced BAEC apoptosis (32%
compared with 33% at 8 h). In contrast, this non-apoptotic dose of
C16-ceramide bypassed the anti-apoptotic effect of VEGF-165
(Figure 1C), VEGF-121 (Figure S3A), and bFGF (Figure S4),
restoring radiation-induced apoptosis to a level comparable to
10 Gy alone. C16-dihydroceramide (1 mM), which differs from
ceramide by a double bond in the sphingoid base backbone, had
no effect on VEGF and bFGF inhibition of radiation-induced
BAEC apoptosis (data not shown). Increasing bFGF up to 8 ng/ml
did not alter restitution of radiation-induced apoptosis by C16-
ceramide (Figure S7). Similarly, C16-ceramide bypassed VEGF
and bFGF inhibition of radiation-induced apoptosis in HCAEC
(Figure S5). Taken together, these studies indicate inhibition of
ASMase-mediated ceramide elevation as the mechanism of the
anti-apoptotic effect of VEGF and bFGF in endothelial cells.
VEGF regulates a pro-apoptotic ceramide rheostat via
ASMase repression
To further explore the modulation of the pro-apoptotic function
of ceramide by VEGF, we employed the commonly used
VEGFR2 antagonistic monoclonal antibody DC101[15]. Initial
studies showed that A19 BAEC used here, like other endothelial
cells[16,17,18], synthesize and secrete VEGF into the culture
medium, predominantly biologically-active VEGF-165, and small
amounts of VEGF-121 (data not shown). A maximal dose of
5 mg/ml DC101 induced a rapid increase of ASMase activity in
BAEC to 402618 nmol/mg/min (Figure 2A;p ,0.005 vs.
control) and subsequently increased ceramide mass (p,0.001 vs.
control at $4h ,Figure 2B), peaking at 1003650 pmol/10
6 cells
at 18 h. Ceramide elevation was DC101 dose-dependent over the
range of 0.4–1 mg/ml, inhibitable by bFGF (Figure S8) within the
range of 1–8 ng/ml (Figure S9). DC101 (5 mg/ml) also induced
apoptosis (Figure 2C), increasing steadily to a peak of 4362% at
24 h (p,0.001 vs. control).
The pivotal role of ceramide in induction of endothelial
apoptosis by DC101 was supported by disrupting pre-formed
plasma membrane glycosphingolipid-enriched domains (GEMs),
the putative site of ceramide generation after ASMase
activation[19,20]. Pre-treatment (30 min) with the cholesterol
binding agent nystatin (30 mg/ml) abolished the apoptogenic
effect of DC101 (Figure 2D)a ta l ld o s e su pt o5mg/ml, sig-
nificantly reducing apoptosis from 3062% to 961% (p,0.005).
Furthermore, the anti-ceramide antibody MAS0020, which
binds ceramide on the cell surface[21], significantly inhibited
DC101-induced apoptosis up to 1 mg/ml (Figure 2E;
p,0.01), exhibiting a dose modifying factor within the
range of 4–5, a large effect. Furthermore, bFGF inhibition of
Anti-Angiogenic Radiosurgery
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ceramide (Figure 2F). Thus three independent approaches to
inactivating ceramide, bFGF/VEGF inactivation of ASMase
translocation, nystatin disruption of GEMs, and binding
ceramide on the cell surface with an anti-ceramide antibody,
all show ceramide signaling is critical to the pro-apoptogenic
effect of DC101.
Anti-angiogenic treatment (DC101) radiosensitizes via
ASMase activation
We also tested combining DC101 with radiation on ceramide
elevation and apoptosis in BAEC. For these studies, DC101 was
titrated to a dose of 0.2 mg/ml that yielded no significant apoptosis
alone. When combined with radiation, 0.2 mg/ml DC101
significantly enhanced radiation-induced ceramide elevation
Figure 1. VEGF inhibits radiation-induced apoptosis via repression of ASMase activation. (A) ASMase activity following 10 Gy is inhibited
by VEGF pre-treatment. Irradiated BAEC samples were collected at the indicated times and ASMase activity measured by quantifying conversion of
[
14C]sphingomyelin to the product [
14C]phosphocholine. Data (mean6s.d.) represent duplicate determinations from 2 experiments. (B) Radiation-
induced ceramide generation is inhibited by VEGF pre-incubation. VEGF (1 ng/ml) was added 15 min before irradiation. Ceramide was quantified at
the indicated times by the diacylglycerol kinase assay. Data (mean6s.d.) represent triplicate determinations from 2 experiments. (C, D) VEGF pre-
treatment inhibits radiation-induced apoptosis. C16-ceramide (C16,1mM) was added 30 min prior to irradiation. Samples were fixed in 10%
paraformaldehyde prior to bis-benzimide staining. For apoptosis quantification, data (mean6s.d) represent duplicate determinations of at least 400
bis-benzimide stained nuclei counted from 2 experiments. Caspase 3 activity was measured by quantitation of the luminescence of cleaved DEVD-
AMC substrate. Data (mean6s.d.) represent duplicate points from 3 experiments.
doi:10.1371/journal.pone.0012310.g001
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slower decay in ceramide levels following irradiation (Figure 3A),
and increased radiation-induced apoptosis at all radiation doses up
to 10 Gy (Figure 3B), providing a dose-modifying factor of
2.060.3. This combined effect was attenuated by 350 ng/ml of
the MAS0020 anti-ceramide antibody, which reduced the
apoptosis induced by 5 Gy plus 0.2 mg/ml DC101 at 8 h from
3262.3% to 1361% (Figure 3C;p ,0.001 vs. 5 Gy+DC101),
indicating the centrality of ceramide in initiating radiation-induced
apoptosis in BAEC. Similar responses were observed in HCAEC
(Figure S10). The observation that VEGF does not inhibit
apoptosis if ceramide elevation is not suppressed (as upon
exogenous ceramide addition), nor do anti-angiogenics sensitize
if ceramide function is abrogated (as by treatment with anti-
ceramide antibody), implies a fundamental role for a ceramide
rheostat in radiation-induced endothelial apoptosis.
ASMase is required for radiosensitization by anti-VEGF
effectors in vivo
As the cell culture studies indicated radiation and anti-
angiogenic reagents act in concert to increase endothelial
apoptosis via the ceramide rheostat, we tested whether anti-VEGF
Ab G6-31 and anti-VEGF receptor Ab DC101 similarly amplify
the vascular component of tumor response in vivo. We employed
the mouse MCA/129 fibrosarcoma, previously shown by us to
engage the vascular component in response to single dose
radiotherapy, with 45–50% local tumor cures achieved with a
single dose of 15 Gy[6]. In Figure 4A a single dose of 14.5 Gy
resulted in 2 of 6 (33%) tumors showing an initial complete
response and apparent local tumor cure at 90 days post
radiotherapy, while the remaining exhibited tumor growth delay
or no response. Pre-treatment with G6–31 (5 mg/kg)[22]
delivered intravenously 1 h prior to radiation, significantly
radiosensitized tumor response, with all tumors demonstrating
an initial complete response, and with 3 of 5 (60%) maintaining
local cure at 90 days (Figure 4B;p ,0.001 vs. radiation alone).
G6–31 alone did not affect unirradiated tumor growth (not
shown). Combining G6–31 with a lower radiation dose of
13.5 Gy, which by itself conferred minimal tumor growth delay
but no local cures (not shown), also resulted in synergistic
enhancement of tumor response, yielding 2 of 5 (40%) cures at
90 days, and the rest exhibiting growth delay of 27 days (not
shown and Figure 4C;p ,0.001 compared to radiation alone).
To put these data in perspective, in total we have evaluated 75
MCA/129 fibrosarcomas that received 13.5 Gy+isotype control
antibody without detecting a single local cure. It should be noted
that MCA/129 fibrosarcomas growing in asmase
2/2 littermates
were completely resistant to the radiosensitizing effects of G6–31
(Figure 4D). Additionally, anti-ceramide Ab MAS0020, injected
immediately before irradiation, abrogated G6–31 radiosensitiza-
tion, phenocopying the ASMase knockout mice (Figure 4E).
These observations confirm that anti-angiogenic tumor radiosen-
sitization in vivo requires ASMase-mediated ceramide generation.
Similar radiosensitization was observed following pre-treatment
with DC101. While 1600 mg DC101 per 25 g mouse alone did not
affect unirradiated tumor growth (not shown), its intravenous
delivery 1 h prior to 13.5 Gy significantly radiosensitized the tumor
(Figure 5A), yielding 2/9 cures for at least 90 days and a mean of
18 days growth delay in the 7 remaining mice (not shown). As with
G6–31, MCA/129 fibrosarcoma grown in asmase
2/2 littermates
were completely resistant to 13.5 Gy6DC101 (Figure 5B), and
anti-ceramide MAS0020 antibody injected immediately before
irradiation abrogated the radiosensitizing effect of DC101 (not
shown). Similarly, B16 melanoma, previously reported to engage
a vascular component in response to single dose radiothera-
py[6], is radiosensitized by DC101 (Figure S11), but when
implanted in bak
2/2 mice, which provides radioresistant
vasculature [8], similarly exhibited resistance to DC101-induced
radiosensitization.
To confirm that anti-VEGF or anti-VEGFR2 increased
radiation-induced endothelial cell apoptosis in vivo, MCA/129
tumors were excised at 4–6 h post-irradiation and co-stained with
an antibody to the endothelial selective cell surface marker CD34
(blue in Figure S12) and TUNEL for apoptosis (brown), as
described[6]. Neither G6–31 (not shown), nor DC101 (Figure
S12) conferred tumor endothelial apoptosis when delivered alone.
Pre-treatment with G6–31, increased endothelial apoptosis at 6 h
post 14.5 Gy from 2461.7% to 39.562.5% (Figure 5C;
p,0.001), and DC101 enhanced apoptosis 3-fold at 6 h after
13.5 Gy (Figure 5D,p ,0.001 vs. radiation alone). In contrast,
neither radiation dose in the presence or absence of anti-
angiogenic drugs had an impact on endothelial cell apoptosis in
tumors grown in asmase
2/2 mice (data not shown). FACS analysis
of single cell suspensions of disaggregated MCA/129 fibrosarco-
mas grown in asmase
+/+ and asmase
2/2 mice revealed similar
numbers of CD31+/VEGFR2+ endothelial cells (Figure S13),
and immunohistochemistry revealed that the vasculature of
fibrosarcomas grown in asmase
2/2 mice displays a normal pattern
of VEGFR2 expression, and normal VEGFR2 tyrosine phos-
phorylation upon intravenous VEGF injection (data not shown).
Hence failure to respond to DC101 in an asmase
2/2 background
cannot be attributed to VEGFR2 function deficiency. Taken
together, these observations are consistent with the mechanism of
tumor radiosensitization by anti-VEGF effectors acting via
amplification of the vascular component, specifically antagoniz-
ing VEGF that is generically present in tumors, generated by and
secreted from tumor cells[23].
Timing of anti-angiogenic treatment is critical for
radiosensitizing the vascular component
Whereas the in vitro studies showed that ASMase activation
occurs within 1–2 min of radiation exposure of endothelial cells,
we tested the timing of application of DC101 relative to radiation
delivery. While DC101 pre-trea t m e n ta t1hp r i o rt or a d i a t i o n
induced marked radiosensitization to a single high radiation dose
of 13.5 Gy, DC101 injection 24 or 48 h prior to or at any time
Figure 2. VEGF regulates a pro-apoptotic ceramide rheostat via ASMase repression. (A) ASMase activation in response to DC101. A19
BAEC were incubated with 5 mg/ml DC101 and ASMase activity was measured every 2 h for 24 h by quantifying conversion of [
14C]sphingomyelin to
the product [
14C]phosphocholine as in Fig. 1A. Data (mean6s.d.) represent triplicate determinations from 2 experiments. (B) DC101 (5 mg/ml)
induces ceramide elevation. Ceramide was quantified by the diacylglycerol kinase assay as in Fig. 1B at the times indicated. Data (mean6s.d.)
represent triplicate determinations from 2 experiments. (C) DC101 induces apoptosis. DC101(5 mg/ml) was added and cells collected every 2 h, fixed
and apoptosis quantified using bis-benzimide method as in Fig. 1C.( D) Disruption of GEMs inhibits DC101-induced apoptosis. Nystatin (30 mg/ml)
was added 30 min prior to the addition of escalating doses of DC101 and apoptosis quantified after 24 h as in Fig. 1C.( E) Anti-ceramide antibody
MAS0020 inhibits apoptosis induction by DC101. MAS0020 was added at 250 ng/ml 30 min prior to the addition of increasing concentrations of
DC101. After 24 h, apoptosis was quantified as in Fig. 1C.( F) bFGF inhibits DC101-induced apoptosis by inhibition of ceramide generation. bFGF
(1 ng/ml) and C16-ceramide (1 mM) were added as detailed in Fig. 1C, and apoptosis was quantified after 24 h.
doi:10.1371/journal.pone.0012310.g002
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more detailed kinetic analysis of the DC101 effect revealed
optimal radiosensitization wheni tw a sd e l i v e r e da t0 . 5 – 2hp r e -
irradiation (data not shown). One or two doses of DC101
delivered intraperitoneally during the first week post-irradiation
also had no further impact on tumor growth delay or tumor cure
(data not shown). These studies indicate that anti-VEGF drugs
need to be delivered shortly prior to radiation in order to
radiosensitize, consistent with a requirement to neutralize VEGF
within seconds to minutes after radiation, the time-window when
the ceramide rheostat is activated to initiate the vascular
component of single dose radiotherapy.
Discussion
The present studies define a molecular mechanism for anti-
angiogenic enhancement of tumor response to single dose
radiotherapy via amplification of ceramide-driven endothelial
apoptosis, converting transient tumor response to local cure. As
such, the in vivo studies corroborate the current set of in vitro studies
that identify the ambient ceramide level in the exoplasmic leaflet of
the plasma membrane as dictating whether an angiogenic anti-
apoptotic state or an anti-angiogenic pro-apoptotic state predom-
inates. Both bFGF and VEGF suppress radiation-induced ASMase
activation, ceramide generation and apoptosis, and restoration of
Figure 3. Anti-angiogenic treatment (DC101) radiosensitizes via ASMase activation. (A) DC101-pre-treatment increases radiation-induced
ceramide elevation. Cells were pre-treated for 16 h with 0.2 mg/ml DC101, irradiated at 8 Gy, and ceramide was measured by diacylglycerol kinase
assay as in Fig. 1B. Data (mean6s.d.) represent triplicate determinations from 2 experiments. (B) DC101 increases radiation-induced apoptosis. Cells
were pre-incubated for 16 h with 0.2 mg/ml DC101. At 8 h post-irradiation, apoptosis was quantified using bis-benzimide staining. (C) Anti-ceramide
antibody inhibits DC101-enhanced radiation-induced apoptosis. BAEC were treated with 350 ng/ml MAS0020 15 min prior to 0.2 mg/ml DC101, and
after 16 h irradiated at 5 Gy. Apoptosis was quantified 8 h post-irradiation by bis-benzimide staining. Data in (2C–F, 3A, and 3C) represent
means6s.d. of duplicate determinations from at least 400 scored nuclei from 2 separate experiments.
doi:10.1371/journal.pone.0012310.g003
Anti-Angiogenic Radiosurgery
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apoptosis even in continued presence of VEGF/bFGF. The
ability to reverse the bFGF/VEGF effect by provision of the
product of the enzymatic reaction regulated by ASMase
definitively identifies ceramide, and not some other factor
regulated by these pro-angiogenic growth factors, as conferring
their anti-apoptotic potential. The studies thus indicate that
radiation-induced apoptosis requires at least two signals, ceramide
generation at the plasma membrane and a set of other, as yet
unknown, events engaged upon radiation exposure. Furthermore,
the fact that ceramide elevation ‘‘trumps’’ VEGF/bFGF suppres-
sion, and that it is requisite for anti-angiogenic radiosensitization,
defines a ceramide rheostat that regulates the balance between
endothelial cell survival and death, and ultimately tumor radiation
response.
Although the current studies do not address the mechanism of
radiation-induced translocation/activation of ASMase, a great
deal of information has been published over the last decade that
sheds light on this event. Diverse stresses (cytokines, heat, UV,
ionizing radiation etc.) induce ASMase trafficking to the outer
leaflet of the plasma membrane, where it finds its target
sphingomyelin[20,24,25]. This process requires intact microtu-
bules[26], phosphorylation of Ser508 of ASMase[27], as well as
functional lipid rafts[28]. Ceramide generation in the outer plasma
membrane leads to formation of ceramide-rich macrodomains
(CRMs)[25,26], that form within seconds to minutes of stress, are
large (1–5 microns), and serve as sites of stress specific protein
oligomerization[29], although for most stresses little is known
about the specific multiprotein complexes that form therein.
Although the precise target for VEGF inhibition of ASMase
activation remains unknown, it is anticipated that it will be possible
to make progress on this issue in future studies.
Perhaps the most important aspect of these studies is that use of
anti-angiogenic agents as radiosensitizers in vivo was delineated
based on the biology of radiation-induced generation of the pro-
apoptotic second messenger ceramide in cultured endothelial cells.
In this regard, the generation of ceramide within minutes of
irradiation predicted that anti-angiogenic drugs should be
Figure 4. ASMase is required for anti-VEGF (G6–31) mAb radiosensitization in vivo. (A and B) Impact of 1 h pre-treatment with G6–31
(5 mg/kg) on tumor response to 14.5 Gy. N equals number of animals per group. (C and D) Impact of a 1 h pre-treatment with G6–31 (5 mg/kg) on
tumor response to 13.5 Gy using tumor xenografts grown in asmase
+/+ (left panel) or asmase
2/2 littermates (right panel). No tumor growth delay was
observed in tumors growing in ASMase deficient mice after 13.5 Gy pre-treated with G6–31 as compared to tumors growing in the asmase
+/+
littermates. Data (mean6s.e.m.) are collated from 5 animals per group. Arrows indicate the day of treatment. (E) Impact of anti-ceramide treatment
on G6–31-enhanced radiation-response. G6–31 (5 mg/kg) was injected i.v. 1 h before 14.5 Gy irradiation. Anti-ceramide Ab MAS0020 (25 mg) was
injected i.v. immediately before irradiation. Anti-ceramide treated mice displayed a significantly reduced tumor growth delay. Data (means 6 s.e.m.)
were collated from 4 mice per group.
doi:10.1371/journal.pone.0012310.g004
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acutely, yet not allow the system time to counterregulate, damping
down the ceramide rheostat to a new level only slightly more
sensitive than the original setting. Consistent with a need to deliver
anti-angiogenic drugs just prior to irradiation is the empiric
observation that pre-treatment of mice harboring tumors with
DC101 at more than 2 h prior to or at any time after irradiation
resulted in loss of radiosensitization. This temporal relationship
between anti-angiogenic agents and radiation is inconsistent with
the tumor microvessel normalization hypothesis, which requires at
least 24 h to manifest[4,30], and also with the proposed use of
anti-angiogenics to prevent endothelial progenitor recruitment
into the damaged site, usually delivered at 24 h prior to
irradiation.
Combining radiation and anti-angiogenic radiosensitization
may have practical clinical applications. Emerging evidence
indicates that single dose radiotherapy, such as used in the present
studies, may provide therapeutic benefit to some human tumors,
even tumors considered resistant to conventional fractionated
radiotherapy schemes. Early clinical experience with single dose
radiotherapy in oligometastatic human cancers has demonstrated
that local control of ,90% can be achieved with single doses of
Figure 5. Role of ASMase in anti-angiogenic therapy. (A) Impact of a 1 h pre-treatment with DC101 (1600 mg/animal) on the tumor response
to 13.5 Gy using MCA/129 fibrosarcomas grown in asmase
+/+ or (B)i nasmase
2/2 littermates. Data (mean6s.e.m.) are collated from asmase
+/+ control
mice (n=7), DC101-treated asmase
+/+ mice (n=9), and asmase
2/2 mice (n=10 each). (C) Quantification of the G6–31 effect on radiation-induced
endothelial cell apoptosis. Endothelial cells (mean6s.e.m.) from cross sections of 14.5 Gy-irradiated MCA/129 fibrosarcomas were stained with both
an endothelial cell specific Ab (MECA-32) and TUNEL. Data was collated from 20 fields from 1 of 2 similar experiments employing 2 animals per group
at the times shown. (D) Quantification of the effect of DC101 on 13.5 Gy radiation-induced endothelial cell apoptosis. Data (mean6s.e.m.) represent
TUNEL-positive endothelial cells collated from 20 fields from 1 of 2 similar experiments employing 2 animals per group.
doi:10.1371/journal.pone.0012310.g005
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are achieved across a large variety of human tumor phenotypes,
regardless of histologic classification. Other studies have employed
three exposures of 12–20 Gy in treatment of a large variety of
human cancers (the hypofractionated approach), demonstrating
increasing local control rates as the dose per fraction escalated[32].
Because of the technical complexity associated with delivery of
24 Gy in a single session, there has been an ongoing search for
tumor radiation sensitizers that would enable use of lower dose per
fraction via currently affordable technologies, preserving the
improved outcome provided by the higher exposures of single
dose or hypofractionated schemes. In this context, it should be
noted that several anti-angiogenic drugs have recently been
developed for human use and are either in clinical use or currently
being evaluated in clinical trials[1]. The present studies define a
biologic basis for use of anti-angiogenic reagents in combination
with high-dose ($10 Gy) irradiation, given either as single dose or
by the hypofractionated approach, providing an opportunity to
further improve these emerging modalities. Specificity towards
tumor versus normal tissue is currently realized by image-guided
radiotherapy (IGRT) that targets the radiation beam onto the
tumor with precision, nearly completely excluding surrounding
normal tissues. Based on the principles defined in the present
studies, clinical trials are currently being planned at MSKCC to
employ anti-VEGF drugs as radiosensitizers, delivered immedi-
ately prior to radiotherapy. These studies are designed to explore
the feasibility of de-escalating the dose levels of single dose-IGRT
without compromising local tumor control.
Materials and Methods
Cell culture experiments
Cloned populations of bovine aortic endothelial cells (BAEC),
obtained as previously described[33] and cultured in DMEM sup-
plemented with 10% calf serum, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine at 37uC in a humidified
10% CO2 chamber. Unless otherwise stated, all other cell culture
products were obtained through Mediatech. For experiments,
BAEC were pre-incubated overnight in DMEM containing 0.2%
human albumin. Human coronary aortic endothelial cells
(HCAEC) were obtained from Cambrex and grown in EBM-2
medium with EGM-2 MV SingleQuot supplement (Cambrex) at
37uC in a humidified 5% CO2 chamber. For experiments
HCAEC were pre-incubated in EBM-2 medium containing
0.5% FCS overnight. Irradiation of cultured cells was carried
out in Shepherd Mark I irradiator containing a
137Cs source at a
rate of 2.08 Gy/min. For experiments involving incubations for
under 10 min, cells were irradiated on ice and thereafter warmed
in a 37uC water bath for the indicated times. Basic FGF (Scios),
rhVEGF-121 or rhVEGF-165 (R&D Systems) were added to
cultures (1 ng/ml) 10 min before irradiation. For reconstitution of
the ceramide effect, cells were pretreated with 1 mMC 16-ceramide
(Biomol) in dodecane:ethanol (2:98, v/v; 0.05% final concentra-
tion) 30 min before irradiation. DC101 (kindly provided by
ImClone), was added to cells 16 h before irradiation. Anti-
ceramide IgM MAS0020 (Glycobiotech GmbH) was added
15 min before irradiation. To measure ASMase and ceramide
Figure 6. Impact of timing of DC101 addition on the radiation response of MCA/129-fibrosarcomas. DC101 (1600 mg/kg) was injected
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incubated in a 37uC water bath for the indicated times according
to published protocol[34].
Mice and in vivo experiments
asmase
+/+ and asmase
2/2 mice, maintained in an sv129xBl/6
background, were propagated using heterozygous breeding pairs.
Genotyping used a modification of the protocol described[35],
employing a revised PA2 primer (59-GGCTACCCGTGA-
TATTGC-39), and 35 cycles of PCR amplification, each at
94uC for 15 sec, 64uC for 30 sec, and 68uC for 90 sec. Mice were
housed at the animal core facility of Memorial Sloan-Kettering
Cancer Center. This facility is approved by the American
Association for Accreditation of Laboratory Animal Care and is
maintained in accordance with the regulations and standards of
the United States Department of Agriculture and the Department
of Health and Human Services, National Institutes of Health. The
Institutional Animal Care and Use Committee (IACUC) at
Memorial Sloan-Kettering Cancer Center approved the mice
experiments under Protocol #92-10-038 on September 17, 2009.
MCA/129 fibrosarcoma and B16 melanoma cells were
maintained in DMEM high glucose supplemented with 10% fetal
calf serum (FCS), 100 U of penicillin/ml and 100 mg of
streptomycin/ml in 10% CO2 at 37uC. Cells (10
6), resuspended
in PBS, and injected subcutaneously into the right flank as
described[6]. Once tumors reached 100–150 mm
3, mice were
either treated intravenously or not with DC101 (1600 mg) or anti-
VEGF mAb G6–31 (5 mg/kg, kindly provided by Genentech) or
control IgG 1 h before irradiation. Radiation was delivered using
a Philips MG-324 X-ray unit at 105.5 cGy/min (50 cm source to
skin distance). Mice were lightly sedated with ketamine (0.1 mg/g)
and xylazine (0.02 mg/g) and only tumor, surrounding skin and
subcutaneous tissues, were exposed, the rest of the mouse was
shielded using a specialized lead jig. Tumor volume, based on
caliper measurements, was calculated daily according to the
formula of Kim et al. [36].
Quantification of Apoptosis
Morphologic changes in nuclear chromatin of cells undergoing
apoptosis were detected by staining with the DNA-binding
fluorochrome bis-benzimide trihydrochloride (Hoechst-33258), as
described[37] using an Olympus BH2 fluorescence microscope
equipped with a BH2-DMU2UV with Dich Mirror Cube filter.
Alternately, caspase 3 activity was measured using fluorogenic
AFC-tagged caspase-specific substrates purchased from Biovision,
according to manufacturer’s instructions.
To evaluate endothelial apoptosis in vivo, tumor samples were
processed and stained as previously described[6]. Several different
endothelial markers were evaluated for use on 5 mm paraffin
embedded sections in combination with TUNEL; the best signal to
noise ratio was achieved with a monoclonal antibody from
GeneTex (Clone MEC14.7) and MECA-32 (Developmental
Studies Hybridoma Bank, developed under the auspices of the
NICHD and maintained by The University of Iowa, IA).
Ceramide quantification
Upon termination of experiments, cells were washed once with
cold PBS, and lipids were extracted using two 10 min incubations
in 500 ml methanol at 4uC, followed by an equal volume of
chloroform and 0.6 volume of buffered saline solution/EDTA
solution (135 mM NaCl, 4.5 mM KCl, 1.5 mM CaCl2, 0.5 mM
MgCl2, 5.6 mM glucose, 10 mM HEPES pH 7.2, 10 mM
EDTA). Ceramide was quantified using the diacylglycerol kinase
assay as described[38].
ASMase Activity Measurement
ASMase activity was measured as described[39] with a few
minor modifications. 3 mg of sample, including a control sample
boiled for 20 min, were incubated with a mixture contain-
ing 2.5 nmol/ml of sphingomyelin (Indofine) and 3pCi of
[N-methyl-
14C]Sphingomyelin (Amersham) in 45 ml total volume.
After a 1 h-incubation at 37uC, reactions were terminated with
100 ml buffer (CHCl3:MeOH:HCl, 100:100:1 v/v/v), centrifuged
at 2006g, and 45 ml of the upper phase was removed and
radioactivity measured by scintillation counting.
Statistics
Values are expressed as mean6standard deviation unless
otherwise noted. Paired, two-tailed students t tests were calculated
using Prism v4. We considered P values less than 0.05 to be
significant.
Supporting Information
Methods S1 Supplementary Methods
Found at: doi:10.1371/journal.pone.0012310.s001 (0.03 MB
DOC)
Figure S1 bFGF inhibits radiation-induced ASMase transloca-
tion and ceramide generation. (A) Irradiated BAEC samples were
collected at the indicated times and ASMase activity measured by
quantifying conversion of [
14C]sphingomyelin to the product
[
14C]phosphocholine. Data (mean6s.d.) represent duplicate
determinations from 2 experiments. (B) Cells were fixed at the
indicated times post-irradiation, stained with primary ASMase
antibody (sc9815, 1:10 v/v) and FITC-conjugated secondary Ab.
104 FITC-positive cells were counted by FACScan per point. Data
(mean6s.d.) represent duplicate determinations from 2 experi-
ments. (C) Ceramide was quantified at the indicated times after 10
Gy-irradiation by the DAG assay. bFGF was added 10 min before
irradiation. Data (mean6s.d.) represent triplicate determinations
from 2 experiments.
Found at: doi:10.1371/journal.pone.0012310.s002 (1.56 MB TIF)
Figure S2 Ceramide generated in HCAEC in response to 20 Gy
irradiation is inhibited by bFGF, VEGF-121 and -165. HCAEC
were pre-incubated with 1 ng/ml of either bFGF,VEGF-121 or
VEGF-165 10 min before 20 Gy irradiation. Ceramide was
quantified at the indicated times using the diacylglycerol kinase
method. Data (mean 6s.d.) are derived from triplicate determi-
nations, representative of 2 independent experiments. Note that
the Control and 20 Gy data are repeated in each panel for clarity.
Found at: doi:10.1371/journal.pone.0012310.s003 (1.56 MB TIF)
Figure S3 VEGF-121 pre-treatment inhibits radiation-induced
apoptosis. (A) C16-ceramide (1 mM) was added 30 min prior to
irradiation, while VEGF-121 was added 10 min before. At the
indicated times samples were fixed in 10% paraformaldehyde
prior to bis-benzimide staining. Data (mean6s.d) represent
duplicate determinations of at least 400 bis-benzimide stained
nuclei counted from 2 experiments. (B) Caspase 3 activity was
measured at the stated times after 10 Gy-irradiation by
quantification of the luminescence of cleaved DEVD-AMC
substrate. Data (mean6s.d.) represent duplicate points from 3
experiments.
Found at: doi:10.1371/journal.pone.0012310.s004 (1.56 MB TIF)
Figure S4 bFGF pre-treatment inhibits radiation-induced ap-
optosis. C16-ceramide (1 mM) was added 30 min prior to
irradiation, while bFGF (1 ng/ml) was added 10 min before. At
the indicated times, the cells were fixed in 10% paraformaldehyde
Anti-Angiogenic Radiosurgery
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nuclei. Data (mean6s.d) represent duplicate determinations of at
least 400 bis-benzimide stained nuclei counted from 2 experiments.
Found at: doi:10.1371/journal.pone.0012310.s005 (1.56 MB TIF)
Figure S5 bFGF, VEGF-121 and VEGF-165 protect HCAEC
from radiation-induced apoptosis. HCAEC were prepared as
described in the Supplementary Methods. C16-ceramide (0.4 mM)
was added 30 min before irradiation while bFGF (A), VEGF-121
(B) or VEGF-165 (C), all at 1 ng/ml, were added 10 min before
irradiation. Cells were fixed in 10% paraformaldehyde at the times
shown and apoptosis was quantified by bis-benzimide staining.
Data (mean6s.d.) represent duplicate determinations of at least
400 bis-benzimide stained nuclei collated from 2 experiments.
Note that the Control and 20 Gy data are repeated in each panel
for clarity.
Found at: doi:10.1371/journal.pone.0012310.s006 (1.56 MB TIF)
Figure S6 bFGF pre-treatment inhibits radiation-induced cas-
pase 3 activation. C16-ceramide (1 mM) was added 30 min while
bFGF (1 ng/ml) was added 10 min prior to irradiation. Caspase 3
activity was measured by quantification of the luminescence of
cleaved DEVD-AMC substrate. Data (mean6s.d.) represent
duplicate points from 3 experiments.
Found at: doi:10.1371/journal.pone.0012310.s007 (1.56 MB TIF)
Figure S7 Increasing bFGF does not overcome C16-ceramide
restoration of radiation-induced apoptosis in BAEC. C16-ceramide
(C16,1mM) was added 30 min before 10 Gy, while bFGF was
added 10 min before. Apoptosis was quantified 8 h after
irradiation at 10 Gy. Data (means6s.d.) are collated from at least
400 stained nuclei scored from duplicate points from 1 of 2
independent studies.
Found at: doi:10.1371/journal.pone.0012310.s008 (1.56 MB TIF)
Figure S8 bFGF inhibits DC101-induced ceramide increase.
bFGF was maximally effective at inhibiting ceramide generated by
doses of DC101 up to 1 mg/ml. bFGF (1 ng/ml) was added
10 min before DC101, then ceramide was quantified 24 h later
using the diacylglycerol kinase assay. Data (mean 6s.d.) are
derived from triplicate determinations, representative of 2
independent experiments.
Found at: doi:10.1371/journal.pone.0012310.s009 (1.56 MB TIF)
Figure S9 Escalating doses of bFGF do not further inhibit
ceramide generated in DC101-treated BAEC. Escalating doses of
bFGF were added 10 min before 5 mg/ml DC101. Ceramide was
quantified 24 h later by bis-benzimide staining of nuclei. Data
(mean6s.d.) are collated from triplicate determinations from 2
independent experiments.
Found at: doi:10.1371/journal.pone.0012310.s010 (1.56 MB TIF)
Figure S10 Ceramide is required for radiation-induced apopto-
sis of HCAEC. HCAEC were incubated with 350 ng/ml of anti-
ceramide Ab MAS0020 15 min before 20 Gy irradiation.
Apoptotic nuclei were quantified after bis-benzimide staining at
the time points shown. Data (means6s.d.) are collated from 2
independent studies and represent at least 400 stained nuclei
scored from 4 points.
Found at: doi:10.1371/journal.pone.0012310.s011 (1.56 MB TIF)
Figure S11 DC101 radiosensitization requires an apoptosis-
sensitive vasculature. DC101 (1600 mg) was injected i.v. 1 h before
13.5 Gy irradiation of melanoma xenografts, grown in BAK
+/+ or
BAK
2/2 mice that provide a radiosensitive or radioresistant
vasculature, respectively. Tumor size was measured at the times
shown. Data (means6s.e.m.) were collected from groups of 5 mice.
Found at: doi:10.1371/journal.pone.0012310.s012 (1.56 MB TIF)
Figure S12 DC101 enhances radiation-induced endothelial cell
apoptosis. Representative cross sections of MCA/129 fibrosarco-
mas stained with both an endothelial cell specific Ab (anti-CD34,
blue) and TUNEL (brown).
Found at: doi:10.1371/journal.pone.0012310.s013 (1.56 MB TIF)
Figure S13 Tumors grown in ASM
+/+ and ASM
2/2 mice
display similar levels of endothelial cells. Endothelial cells,
identified as being both CD31 and VEGFR2 expressing, were
quantified by FACS analysis using disaggregated fibrosarcoma
tumors prepared as described in the Supplemental Methods.
Found at: doi:10.1371/journal.pone.0012310.s014 (1.56 MB TIF)
Acknowledgments
We thank Dr. Daniel Hicklin and ImClone for their gift of DC101, Dina
Washington and Genentech for G6–31, and Dr. Regina Feldman for
assistance with immunohistochemistry.
Author Contributions
Conceived and designed the experiments: JPT MGB ZF RNK AHF.
Performed the experiments: JPT MGB MK DH BS MC. Analyzed the
data: JPT MK DH BS MC. Wrote the paper: JPT AHF. Revised the
manuscript for important intellectual content: AH-F ZF RNK.
References
1. Sessa C, Guibal A, Del Conte G, Ruegg C (2008) Biomarkers of angiogenesis for
the development of antiangiogenic therapies in oncology: tools or decorations?
Nat Clin Pract Oncol 5: 378–391.
2. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med
285: 1182–1186.
3. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358: 2039–2049.
4. Fukumura D, Jain RK (2007) Tumor microvasculature and microenvironment:
targets for anti-angiogenesis and normalization. Microvasc Res 74: 72–84.
5. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, et al. (2001) Endothelial
apoptosis as the primary lesion initiating intestinal radiation damage in mice.
Science 293: 293–297.
6. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, et al. (2003)
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science
300: 1155–1159.
7. Fuks Z, Kolesnick R (2005) Engaging the vascular component of the tumor
response. Cancer Cell 8: 89–91.
8. Rotolo JA, Maj JG, Feldman R, Ren D, Haimovitz-Friedman A, et al. (2008)
Bax and Bak do not exhibit functional redundancy in mediating radiation-
induced endothelial apoptosis in the intestinal mucosa. Int J Radiat Oncol Biol
Phys 70: 804–815.
9. Tabas I (1999) Secretory sphingomyelinase. Chem Phys Lipids 102: 123–130.
10. Pena LA, Fuks Z, Kolesnick RN (2000) Radiation-induced apoptosis of
endothelial cells in the murine central nervous system: protection by fibroblast
growth factor and sphingomyelinase deficiency. Cancer Res 60: 321–327.
11. Kolesnick R, Fuks Z (2003) Radiation and ceramide-induced apoptosis.
Oncogene 22: 5897–5906.
12. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, et al. (2001)
Inhibition of vascular endothelial growth factor receptor signaling leads to
reversal of tumor resistance to radiotherapy. Cancer Res 61: 2413–2419.
13. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M,
McLoughlin M, et al. (1997) Lipopolysaccharide induces disseminated
endothelial apoptosis ceramide generation. J Exp Med 186: 1831–1841.
14. Gulbins E, Kolesnick R (2003) Raft ceramide in molecular medicine. Oncogene
22: 7070–7077.
15. Witte L, Hicklin DJ, Zhu Z, Pytowski B, Kotanides H, et al. (1998) Monoclonal
antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic
therapeutic strategy. Cancer Metastasis Rev 17: 155–161.
16. Uchida K, Uchida S, Nitta K, Yumura W, Marumo F, et al. (1994) Glomerular
endothelial cells in culture express and secrete vascular endothelial growth
factor. Am J Physiol 266: F81–88.
17. Bocci G, Fasciani A, Danesi R, Viacava P, Genazzani AR, et al. (2001) In-vitro
evidence of autocrine secretion of vascular endothelial growth factor by
Anti-Angiogenic Radiosurgery
PLoS ONE | www.plosone.org 11 August 2010 | Volume 5 | Issue 8 | e12310endothelial cells from human placental blood vessels. Mol Hum Reprod 7:
771–777.
18. Siejka A, Lawnicka H, Komorowski J, Schally AV, Stepien T, et al. (2003) GH-
RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine
endothelial cells. Life Sci 72: 2473–2479.
19. Nix M, Stoffel W (2000) Perturbation of membrane microdomains reduces
mitogenic signaling and increases susceptibility to apoptosis after T cell receptor
stimulation. Cell Death Differ 7: 413–424.
20. Rotolo JA, Zhang J, Donepudi M, Lee H, Fuks Z, et al. (2005) Caspase-
dependent and -independent activation of acid sphingomyelinase signaling. J Biol
Chem 280: 26425–26434.
21. Goggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, et al. (2004)
PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and
ceramide. Nat Med 10: 155–160.
22. Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, et al. (2007) Inhibition of
VEGF-A prevents the angiogenic switch and results in increased survival of
Apc+/min mice. Proc Natl Acad Sci U S A 104: 10625–10630.
23. Ferrara N (1999) Vascular endothelial growth factor: molecular and biological
aspects. Curr Top Microbiol Immunol 237: 1–30.
24. Grassme H, Jekle A, Riehle A, Schwarz H, Berger J, et al. (2001) CD95 signaling
via ceramide-rich membrane rafts. J Biol Chem 276: 20589–20596.
25. Cremesti A, Paris F, Grassme H, Holler N, Tschopp J, et al. (2001) Ceramide
enables fas to cap and kill. J Biol Chem 276: 23954–23961.
26. Grassme H, Cremesti A, Kolesnick R, Gulbins E (2003) Ceramide-mediated
clustering is required for CD95-DISC formation. Oncogene 22: 5457–5470.
27. Zeidan YH, Hannun YA (2007) Activation of acid sphingomyelinase by protein
kinase Cdelta-mediated phosphorylation. J Biol Chem 282: 11549–11561.
28. Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, et al.
(2004) Cisplatin-induced CD95 redistribution into membrane lipid rafts of
HT29 human colon cancer cells. Cancer Res 64: 3593–3598.
29. Gulbins E, Dreschers S, Wilker B, Grassme H (2004) Ceramide, membrane rafts
and infections. J Mol Med 82: 357–363.
30. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, et al. (2004) Kinetics of
vascular normalization by VEGFR2 blockade governs brain tumor response to
radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
Cancer Cell 6: 553–563.
31. Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, et al. (2008)
High-dose, single-fraction image-guided intensity-modulated radiotherapy for
metastatic spinal lesions. Int J Radiat Oncol Biol Phys 71: 484–490.
32. McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, et al. (2008)
Observation of a Dose-Control Relationship for Lung and Liver Tumors After
Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys.
33. Haimovitz-Friedman A, Vlodavsky I, Chaudhuri A, Witte L, Fuks Z (1991)
Autocrine effects of fibroblast growth factor in repair of radiation damage in
endothelial cells. Cancer Res 51: 2552–2558.
34. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, et al. (1996)
Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in
radiation-induced apoptosis. Cell 86: 189–199.
35. Horinouchi K, Erlich S, Perl DP, Ferlinz K, Bisgaier CL, et al. (1995) Acid
sphingomyelinase deficient mice: a model of types A and B Niemann-Pick
disease. Nat Genet 10: 288–293.
36. Kim JH, Alfieri AA, Kim SH, Young CW (1986) Potentiation of radiation effects
on two murine tumors by lonidamine. Cancer Res 46: 1120–1123.
37. Garzotto M, White-Jones M, Jiang Y, Ehleiter D, Liao WC, et al. (1998) 12-O-
tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP cells is mediated
through ceramide synthase. Cancer Res 58: 2260–2264.
38. Garzotto M, Haimovitz-Friedman A, Liao WC, White-Jones M, Huryk R, et al.
(1999) Reversal of radiation resistance in LNCaP cells by targeting apoptosis
through ceramide synthase. Cancer Res 59: 5194–5201.
39. Wiegmann K, Schutze S, Machleidt T, Witte D, Kronke M (1994) Functional
dichotomy of neutral and acidic sphingomyelinases in tumor necrosis factor
signaling. Cell 78: 1005–1015.
Anti-Angiogenic Radiosurgery
PLoS ONE | www.plosone.org 12 August 2010 | Volume 5 | Issue 8 | e12310